Home › All Companies › ANEB › Quarterly Report

Anebulo Pharmaceuticals, Inc. (ANEB) — Quarterly Report

AI-Powered SEC Filing Analysis

← All ANEB filings
Latest Quarterly Report Filed: 2026-02-12

Key Insights

  • Anebulo Pharmaceuticals reported a net loss of $X.X million for the quarter ended December 31, 2025, indicating ongoing development expenses for their lead drug candidate.
  • The company raised $X.X million through a private placement in December 2024, providing additional runway to advance their research and development efforts.
  • Anebulo's stock incentive plan was expanded in April 2025, potentially signaling plans to attract and retain key talent as the company progresses.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Anebulo Pharmaceuticals, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.